Focetria: Interim Phase II/III data

Interim data from an ongoing U.S. Phase II/III trial showed that a single 3.75 µg dose of Focetria met immune response criteria in children ages 3 to 8 at day 22. The trial enrolled 1,360 subjects, 80...